Gamma-globin De-repression via Co-repressor Disruption
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to effectively stimulate or de-repress the gamma-globin gene in definitive erythroid cells, which is crucial for treating beta-globin disorders like sickle cell disease and beta-thalassemia, as existing therapies do not adequately increase gamma-globin production to inhibit polymerization of deoxygenated sickle hemoglobin.
Innovation Solution
A method involving recombinant cells with nucleic acid sequences encoding DNMT1, LSD-1, TR2/TR4 polypeptides, and other co-repressors is used to screen for compounds that disrupt interactions between these proteins and the gamma-globin promoter, thereby stimulating or de-repressing the gamma-globin gene, and administering inhibitors like tranylcypromine or doxorubicin to increase gamma-globin expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing therapies are used to treat beta-globin disorders, then treatment is provided, but gamma-globin production is not adequately increased to inhibit polymerization of deoxygenated sickle hemoglobin
Solution Approach 1:
The patent changes the epigenetic state parameters of the gamma-globin gene by recruiting co-repressor complexes (NuRD, CoREST, HDAC3, TIF1beta) to the gamma-globin promoter. By modifying chromatin structure, histone modifications, and DNA methylation status through these epigenetic mechanisms, the patent achieves de-repression and increased gamma-globin production, thereby improving treatment effectiveness for beta-globin disorders
2Productivity
If compounds are screened to stimulate gamma-globin expression, then gamma-globin production increases, but the complexity of screening methods increases
Solution Approach 1:
The patent extracts and isolates specific co-repressor proteins (DNMT1, LSD-1, TR2, TR4, NuRD, CoREST, HDAC3, TIF1beta) that regulate gamma-globin expression. By focusing on these discrete molecular targets rather than screening entire cellular pathways, the patent simplifies the screening approach while effectively identifying compounds that stimulate gamma-globin production
Solution Approach 2:
The patent uses co-repressor proteins as intermediary targets for compound screening. Instead of directly screening for compounds that activate gamma-globin expression, the patent screens for compounds that disrupt co-repressor binding to the gamma-globin promoter. This intermediary approach simplifies the screening mechanism while achieving the desired outcome of increased gamma-globin production
Data Source
AI summary
This disclosure describes methods of screening for compounds that disrupt the interaction between DNMT1 and the gamma-globin promoter or between LSD-1 and the gamma-globin promoter. This disclosure describes methods of screening for compounds that de-repress the gamma-globin gene.